Financing

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Briefly Bio #Financing #Software

AI data sharing company Briefly Bio launches with $1.2m funding

Briefly Bio, a software company that hopes to make lab work more reproducible by helping scientists capture and share their work, has launched with a $1.2m pre-seed funding round. The financing was led by Compound VC, with participation from NP Hard, Tiny VC and angel investors… Read More

#Business & Investment #News

#Antibody drug conjugate (ADC) #Financing #Francis Crick Institute #Imperial College London #Myricx Bio #Start-ups

Myricx Bio announces £90m ($114m) Series A financing

UK biotech Myricx Bio has raised £90 ($114) million Series A financing to support the development of its N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) therapeutics. The round was co-led by new investors Novo Holdings and Abingworth, with additional support from British Patient Capital, Cancer Research Horizons… Read More

#Business & Investment #News #Trending News

#Artificial intelligence (AI) #Financing #Formation Bio #Investment

AI-driven drug company secures $372m Series D funding

Formation Bio, a tech-driven and AI-native pharma company, has raised $372 million in a Series D financing. The financing was led by a16z with significant participation from Sanofi. Current investors also joined the round, including Sequoia, Thrive, Emerson Collective, and Lachy Groom, along with new investors,… Read More

#Business & Investment #News

#Exsilio Therapeutics #Financing #Genetics / genomics #mRNA #Start-ups

mRNA-based drug company launches with $82 million

Genomic medicine developer Exsilio Therapeutics has emerged from stealth with $82 million in Series A financing. The funding was co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, JP Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures,… Read More

#Business & Investment #News #Start-up Zone

Business financing
#AltruBio #Antibody #Financing #Phase II trial #Ulcerative colitis (UC)

$225m to advance novel immune checkpoint enhancer programme

AltruBio has closed an oversubscribed Series B financing of up to $225 million, which will be used to advance the clinical development of the first-in-class, novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268. The funds will be used to support ongoing and planned Phase II… Read More

#Business & Investment #News

#Aardvark Therapeutics #Financing #Investment #Obesity #Orphan drugs #Rare disease

Funding of $85 million secured for Prader-Willi Syndrome drug

Aardvark Therapeutics has announced an $85 million oversubscribed Series C financing. The funding will be used to complete the clinical trials required for regulatory approval of Aardvark’s lead asset, ARD-101, for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS), as well as to demonstrate… Read More

#Business & Investment #News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

Seed fund
#Clinical trials #Drug discovery #Financing

$75m in funding to develop tenosynovial giant cell tumour mAb 

SynOx Therapeutics has closed a $75m Series B financing round, which will be used to generate registrational Phase III clinical and CMC data for emactuzumab, the company’s potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of tenosynovial giant cell tumour (TGCT).  TGCT is a type… Read More

#News

#Financing #Neurology #Neurosterix #Schizophrenia #Start-ups

$63m for allosteric modulators for neurological disorders

Neurosterix has launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures. The company will acquire Addex’s allosteric modulator discovery technology platform. The platform has a track record of identifying highly… Read More

#Editor's Choice #News #Start-up Zone

#CAR-T #Cell and gene therapy #Cell therapy #Financing #Gene therapy

This week in drug discovery (18-22 March) 

News round-up for 18-22 March by DDW Digital Content Editor Diana Spencer. This has been an interesting week for cell and gene therapies, with two landmark FDA approvals, two significant fundraising efforts and potentially ground-breaking study results in glioblastoma. The top stories: ‘Dual-target’… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Financing #In vivo #Investment

$175M financing will support development of in vivo CAR-T therapies

Biotechnology company Capstan Therapeutics has raised $175 million in an oversubscribed Series B financing. The proceeds will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP… Read More

#Business & Investment #News

#Financing #Mission Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's

£25.2 million raised to progress Parkinson’s treatment

Mission Therapeutics has raised £25.2 ($32.1) million to accelerate development of its lead drug candidates in the area of mitophagy, MTX325 and MTX652, through clinical trials. The financing was jointly led by existing investors Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group,… Read More

#Business & Investment #News